Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.

Publication Type:

Journal Article

Authors:

Sequist, Lecia V; Besse, Benjamin; Lynch, Thomas J; Miller, Vincent A; Wong, Kwok K; Gitlitz, Barbara; Eaton, Keith D; Zacharchuk, Charles; Freyman, Amy; Powell, Christine; Ananthakrishnan, Revathi; Quinn, Susan; Soria, Jean-Charles

Source:

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 28, Issue 18, p.3076-83 (2010)

Keywords:

ADENOCARCINOMA, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, International Agencies, Lung Neoplasms, Male, Middle Aged, Mutation, Prospective Studies, Quinolines, Receptor, Epidermal Growth Factor, Receptor, erbB-2, Survival Rate, Treatment Outcome, Young Adult

Abstract:

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have had a significant impact on non-small-cell lung cancer (NSCLC) outcomes, particularly for patients with EGFR mutations. Resistance emerges after 9 to 12 months, primarily mediated by the T790M resistance mutation. We studied neratinib, an irreversible pan-ErbB TKI that may overcome T790M.